Abstracts and program for the Resverlogix/Apabetalone oral and poster presentations at CTAD-Asia Sept 1-2, 2018 are now available.

Oral presentation: "Cognitive evaluation of treatment effects of the bromodomain and extra terminal domain inhibitor apabetalone: Design and baseline data of the cognition substudy of the BETonMACE Phase 3 cardiovascular trial." 

Poster: "Effect of the BET Protein Inhibitor Apabetalone on Serum Markers of Potential Importance for Cognitive Decline in Cardiovascular Disease Patients."